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We appreciate Professor Rumboldt’s interest in our 
article and his caring comments (1). As he said, most 
published articles propose mitochondrial damage as the 
mechanism of phosphine toxicity; in fact, this hypothesis 
has been repeated in almost every medical article on 
aluminium phosphide (AlP) poisoning since the 1990s (2-
4). To our knowledge, it has not been backed up by any 
studies in humans. Moreover, in vitro studies indicate 
incomplete inhibition of the mitochondrial function (5).
As we know, the main problem with severe AlP 
poisoning is refractory hypotension, which is almost always 
associated with severe refractory metabolic acidosis and 
fatal prognosis (6). There is a general consensus that the 
only possible management is supportive. However, despite 
advanced intensive care strategies, mortality rates vary 
between 24 and 66 % within the first few days (7, 8). This 
urged us to ask ourselves the following:
1. What really happens when phosphine is adsorbed 
by the gastric or pulmonary epithelium?
2. Is inhibition of cytochrome c oxidase really 
addressing the toxicity of AlP?
3. Considering the high mortality rate, are the current 
treatment protocols justified?
To answer these questions let us review the related 
pathological events. In our experience, accumulation of 
serous fluid in the pleural and peritoneal cavities is 
common. Literature reports congestion of the vital organs 
as the most prominent finding in autopsy examinations (9, 
10). In our opinion, this points to the disruption of vascular 
integrity as soon as the absorbed phosphine enters the 
bloodstream. This condition can explain the rapid progress 
of hypotension, which is usually refractory to treatment 
with crystalloid solutions and vasopressors. Refractory 
hypotension leads to circulatory failure and consequently 
metabolic acidosis. In this condition, cell metabolism will 
decrease to enhance the chance of cell survival (11). Even 
though our hypothesis has not yet been tested, it explains 
every fact about AlP poisoning.
One such fact is that current treatment protocols are not 
addressing the problem. Almost all of them repeat the 
ancient errors and often fail to alleviate poisoning symptoms 
(12-14). We recently evaluated misconceptions such as 
using of charcoal, gastric lavage with KMnO4 solution, and 
cardioactive steroids in managing AlP poisoning-induced 
heart failure (12-14) and decided not to follow these 
protocols in our patients.
Jaiswal et al. (6) report that 12 of the 14 patients 
presenting with hypotension died despite intensive care. In 
our experience, successful treatment of hypotension is 
usually associated with the improvement of lactic acidosis 
and patient survival. We propose Voluven® administration 
(6 % hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride) 
at doses from 10 to 15 mL kg-1 body weight, without 
concomitant administration of additional doses of 
bicarbonate at arterial pH>7. However, we can not speak 
about “no need for administration of additional bicarbonate” 
at arterial pH <7, as none of our patients had an arterial pH 
below seven on admission. We would like to make clear 
that in addition to Voluven we administered normal saline 
in dosages as high as 4000-5000 mL over the first 24 hours 
to resuscitate the volume as well as other acceptable 
treatments such as magnesium sulphate, calcium gluconate, 
and N-acetyl cysteine. We would also like to make clear 
that when we as a referral hospital receive our patients, 
most of them have already received considerable doses of 
sodium bicarbonate and even vasopressors before 
admission. 
We are agree with Professor Rumboldt that crystalloid 
solutions are better tolerated than colloidal, but disagree 
that “they are equally effective plasma expanders” in AlP 
poisoning treatment. In fact, considering that compromised 
vascular integrity is the main mechanism of phosphine-
induced haemodynamic failure, only high molecular weight 
plasma expanders can remain in blood vessels.
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In his letter Professor Rumboldt has expressed concern 
about worsening the patients’ prognosis, referring to the 
article by Hartog et al. “Concerns over use of hydroxyethyl 
starch solutions” (15). To address his concern, we read this 
and other articles arguing against the use of HES in critically 
ill patients (16-20). Most of the concerns raised refer to 
coagulopathy, acute kidney injury, and increased mortality. 
Jonville-Bera et al. (16) suggest that HES administration 
of more than 33 mL kg-1 day-1, or the cumulative dose more 
than 80 mL kg-1 may be induce coagulopathy. In our 
patients, generally lower doses sufficed to overcome 
refractory hypotension. Therefore, this may not be an 
important issue. Rioux et al. (17) showed that administration 
of more than 14 mL kg-1 was associated with acute kidney 
injury in 10 % of patients treated with a 10 % Pentastarch 
solution (250 kDa/0.45) following cardiac surgery. 
Considering the high mortality of acute AlP poisoning, we 
believe that an even higher acute kidney injury rate may be 
acceptable if this treatment strategy saves the patient’s life. 
Other studies compare 90-day mortality in severe sepsis 
patients receiving more than 2500 mL of HES vs. crystalloid 
solutions in the first four days of treatment. Myburgh et al. 
(18) found no significant difference in mortality rates 
between the treatments; Perner et al. (19) did; whereas 
Guidet et al. (20) reported that HES product needed less 
volume (generally more than 1000 mL) and stabilised the 
haemodynamics more rapidly than normal saline in severe 
sepsis patients at similar mortality rates. In contrast, 
administration of 500-1000 mL of Voluven within the first 
6-12 hours sufficed to stabilise our patients.
It is only fair to admit, however, that our successful 
experience with HES solutions in AlP poisoning is limited 
to only five cases. Considering the poor prognosis of AlP; 
we believe that more remains to be learned from future 
randomised trials that would show the specific properties 
HES. If it proves successful, we could introduce this remedy 
as an antidote, even if its other uses are contraindicated.
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